About: Enhancement of skin permeability with thermal ablation techniques: concept to commercial products

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Enhancement of skin permeability with thermal ablation techniques: concept to commercial products Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Enhancement of skin permeability with thermal ablation techniques: concept to commercial products
Creator	Mandru, Aishwarya Parhi, Rabinarayan
Source	PMC
abstract	Traditionally, the skin is considered as a protective barrier which acts as a highly impermeable region of the human body. But in recent times, it is recognized as a specialized organ that aids in the delivery of a wide range of drug molecules into the skin (intradermal drug delivery) and across the skin into systemic circulation (transdermal drug delivery, TDD). The bioavailability of a drug administered transdermally can be improved by several penetration enhancement techniques, which are broadly classified into chemical and physical techniques. Application of mentioned techniques together with efforts of various scientific and innovative companies had made TDD a multibillion dollar market and an average of 2.6 new transdermal drugs are being approved each year. Out of various techniques, the thermal ablation techniques involving chemicals, heating elements, lasers, and radiofrequency (RF) are proved to be more effective in terms of delivering the drug across the skin by disrupting the stratum corneum (SC). The reason behind it is that the thermal ablation technique resulted in improved bioavailability, quick treatment and fast recovery of the SC, and more importantly it does not cause any damage to underlying dermis layer. This review article mainly discussed about various thermal ablation techniques with commercial products and patents in each classes, and their safety aspects. This review also briefly presented anatomy of the skin, penetration pathways across the skin, and different generations of TDD. [Figure: see text]
has issue date	2020-07-21(xsd:dateTime)
bibo:doi	10.1007/s13346-020-00823-3
bibo:pmid	32696221
has license	no-cc
sha1sum (hex)	8997414f7d165428c7f6180b23c0d8333e5592a9
schema:url	https://doi.org/10.1007/s13346-020-00823-3
resource representing a document's title	Enhancement of skin permeability with thermal ablation techniques: concept to commercial products
has PubMed Central identifier	PMC7372979
has PubMed identifier	32696221
schema:publication	Drug Deliv Transl Res
resource representing a document's body	covid:8997414f7d165428c7f6180b23c0d8333e5592a9#body_text
is schema:about of	named entity 'skin' named entity 'layer' named entity 'innovative' named entity 'protective barrier' named entity 'Application' named entity 'stratum corneum' named entity 'times' named entity 'highly' named entity 'drug' named entity 'drug delivery' named entity 'ablation' named entity '2.6' named entity 'drug molecules' named entity 'radiofrequency' named entity 'stratum corneum' named entity 'commercial' named entity 'epoxy resin' named entity 'oral bioavailability' named entity 'Er:YAG laser' named entity 'thermal energy' named entity 'intramuscular injection' named entity 'first-generation' named entity 'interstitial fluid' named entity 'drug molecules' named entity 'permeation' named entity 'ablate' named entity 'lipid bilayer' named entity 'laser' named entity 'external stimuli' named entity 'absorption coefficient' named entity 'minimally invasive' named entity 'macromolecules' named entity 'drug delivery' named entity '2.6' named entity 'surface area' named entity 'electrosurgery' named entity 'permeation' named entity 'hydrophilic' named entity 'blood vessels' named entity 'neodymium' named entity 'non-invasive' named entity 'phonophoresis' named entity 'keratinocytes' named entity 'clinical trials' named entity 'transdermal' named entity 'inflammatory' named entity 'peptides' named entity 'lipid bilayers' named entity 'erythema' named entity 'permeation' named entity 'low molecular weight' named entity 'hypodermis' named entity 'diclofenac' named entity 'transdermal delivery' named entity 'lipids' named entity 'electric field' named entity 'Tixel' named entity 'Australia' named entity 'hydrophilic' named entity '5-aminolevulinic acid' named entity 'lipophilicity' named entity 'permeation' named entity 'Preclinical studies' named entity 'permeation' named entity 'buprenorphine' named entity 'HBsAg' named entity 'cauterization' named entity 'oleic acid' named entity 'first-generation' named entity 'controlled oxidation' named entity 'body contouring' named entity 'harmful effects' named entity 'non-invasive' named entity 'verapamil' named entity 'Altea' named entity 'corneocytes' named entity 'Altea' named entity 'nude mouse' named entity 'active ingredients' named entity 'Lod, Israel'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software